The products acquired consist of the QuickCat thrombus aspiration catheter, ThromCat thrombectomy device and SafeCross products used to treat chronic total occlusions.
John Schulte, Spectranetics’s president and CEO, said: “The closing was completed ahead of schedule and integration activities have already been initiated.
“Training of many of our vascular intervention sales professionals has been completed and we look forward to marketing the acquired products and maximizing their potential with the manufacturing and product development support of Kensey Nash.”